Navigation Links
HumanZyme® Announces Human Cell-Expressed Interferon gamma for Immunology and Immunotherapy Research Applications
Date:9/26/2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine® Interferon gamma (IFN gamma) expressed from HEK293 cells. IFN gamma, also known as Type II interferon, protects against bacterial, viral and protozoan infections, and is produced by TH-1 or NK cells. Important research is underway on the immunomodulatory activity of IFN gamma, including stimulation of cell-based immunity and cytotoxicity. IFN gamma has been evaluated for use in a variety of clinical applications including as an anti-cancer biotherapeutic, and is FDA approved for the treatment chronic granulomatous disease (CGD) and severe, malignant osteoporosis.

According to Scott Coleridge, CEO at HumanZyme, “Recombinant human IFN-beta is the latest offering in a series of new, high-quality, HEK293-expressed cytokines that are difficult to manufacture. Using our proprietary HEK293 expression system, we are proud to be one of only a few commercial suppliers to offer tag-free recombinant human Interferon gamma expressed in human cells for research purposes. The new IFN gamma further expands our recombinant human interferon product offering to include IFN alpha 2a, IFN alpha 2b, IFN beta, and now IFN gamma.”

IFN gamma has two N-linked glycosylation sites, Asn-25 and Asn-97, on the surface of the dimer, and glycosylation is essential to its half-life in human serum and its full biological activity. Producing IFN gamma in HEK293 cells assures native human processing, glycosylation and folding of the purified protein compared to non-human bacterial and mammalian cell lines, or insect cell expression systems. HumanZyme’s HumanKine proteins are high quality, are animal-derived product free, xeno-free and carrier-free, and are available in bulk.

For more information, see our Interferon gamma product page.

About HumanZyme, Inc.
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14736027.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. HumanZyme® Launches New XKine™ Recombinant Protein Line Expanding Reagents For Stem Cell Research and Regenerative Medicine Applications
2. HumanZyme® Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research Applications
3. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
4. Annual Conference about Technology Solutions for People with Disabilities Announces Program
5. Probiotic Action Announces Probiotics Lead the Digestive Health Market
6. Verenium Announces Preliminary Financial Results For Fiscal 2012
7. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
8. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
9. EAG Announces New General Manager of Release-To-Production (RTP) Division
10. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
11. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... (PRWEB) , ... October 04, 2018 , ... ... diagnostics with genomics, along with Duke University, announced today at IDWeek™ 2018 the ... test that detects pathogen DNA in plasma, accurately identified causative pathogens in patients ...
(Date:10/2/2018)... ... October 02, 2018 , ... Finalists for ... (Locus Bio-Energy) AssurEOR product line was chosen for its advancements in the production ... honor leading innovations in upstream oil applications that are positively impacting the industry. ...
(Date:9/28/2018)... ... September 28, 2018 , ... LabRoots , ... and scientists from around the world, is excited to announce Daniel Andrade, a ... as the winner of the LabRoots Summer 2018 Textbook Scholarship, awarding him $1,000 ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend at ... Mobile Technology, Inc. announced they will formally merge companies and integrate their technologies ... (TB) and other diseases. These two social enterprise corporations, both of which focus ...
Breaking Biology Technology:
(Date:10/13/2018)... ... 2018 , ... uBiome, the leader in microbial genomics, announces ... Medical Advisory Board. Joining the board of leading scientists and doctors from around ... surgical treatments of ulcerative colitis and Crohn's disease. The appointment will help uBiome ...
(Date:10/11/2018)... ... October 09, 2018 , ... ? Smart Health Innovation Lab’s ... path to health system adoption and insurer reimbursement, ? Redox’s integration platform helps ... applications, enabling them to focus on innovation not integration, ? By gaining access ...
(Date:10/11/2018)... ... October 09, 2018 , ... Exalto Bearings UK, the manufacturer ... appointment of Mike Cosgrove as Business Manager. , Cosgrove has over 30 years of ... to day running of the Derby UK facility. , “We are pleased to have ...
Breaking Biology News(10 mins):